<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5838934</article-id><article-id pub-id-type="publisher-id">4039</article-id><article-id pub-id-type="doi">10.1186/s12885-018-4039-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lee</surname><given-names>Dae-Won</given-names></name><address><email>silver2sky@hanmail.net</email></address></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lee</surname><given-names>Kyung-Hun</given-names></name><address><email>drleekh@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hee-Jun</given-names></name><address><email>heejun.dino11@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Tae-Yong</given-names></name><address><email>ktyong@hanmail.net</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jin-Soo</given-names></name><address><email>gistmd@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Han</surname><given-names>Sae-Won</given-names></name><address><email>saewonhan@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oh</surname><given-names>Do-Youn</given-names></name><address><email>ohdoyoun@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jee Hyun</given-names></name><address><email>jhkimmd@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Im</surname><given-names>Seock-Ah</given-names></name><address><email>moisa@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Tae-You</given-names></name><address><phone>82-2-2072-3943</phone><email>kimty@snu.ac.kr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0302 820X</institution-id><institution-id institution-id-type="GRID">grid.412484.f</institution-id><institution>Department of Internal Medicine, </institution><institution>Seoul National University Hospital, </institution></institution-wrap>101 Daehang-ro, Jongno-gu, Seoul, 110-744 South Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0470 5905</institution-id><institution-id institution-id-type="GRID">grid.31501.36</institution-id><institution>Cancer Research Institute, </institution><institution>Seoul National University College of Medicine, </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0789 9563</institution-id><institution-id institution-id-type="GRID">grid.254224.7</institution-id><institution>Department of Internal Medicine, </institution><institution>Chung-Ang University College of Medicine, </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.412479.d</institution-id><institution>Department of Internal Medicine, </institution><institution>Seoul Metropolitan Government Seoul National University Boramae Medical Center, </institution></institution-wrap>Seoul, South Korea </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0647 3378</institution-id><institution-id institution-id-type="GRID">grid.412480.b</institution-id><institution>Department of Internal Medicine, </institution><institution>Seoul National University Bundang Hospital, </institution></institution-wrap>Seongnam, South Korea </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>18</volume><elocation-id>252</elocation-id><history><date date-type="received"><day>17</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2018</year></date></history><permissions><copyright-statement>&#169; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicenter, open-label, single-arm phase II trial that evaluated the efficacy of S-1 and oxaliplatin (SOX) in advanced hepatocellular carcinoma. All patients included in the present study were systemic treatment-na&#239;ve. Prior treatment with sorafenib was allowed, but other treatments were not.</p></sec><sec><title>Methods</title><p id="Par2">Patients received S-1 (40&#160;mg/m<sup>2</sup> twice daily from day 1&#8211;14) and oxaliplatin (130&#160;mg/m<sup>2</sup> on day 1) every 3&#160;weeks. The primary end point was time to progression (TTP). Secondary end points included progression-free survival, overall survival (OS), response rate, and safety profile.</p></sec><sec><title>Results</title><p id="Par3">Thirty six patients with advanced hepatocellular carcinoma were included in this study. The median TTP was 3.0&#160;months (95% confidence interval (CI), 0.75&#8211;5.25), and the median OS was 10.3&#160;months (95% CI, 6.4&#8211;14.3). Bone metastasis was associated with poorer TTP and OS. The efficacy of SOX was unaffected by prior sorafenib or locoregional therapy. The objective response rate was 13.9%. No grade 4 toxicity or death from adverse events occurred. The most common grade 3 toxicities were neutropenia (13.9%), thrombocytopenia (13.9%), and diarrhea (8.3%).</p></sec><sec><title>Conclusions</title><p id="Par4">Although this trial did not meet its primary end point, the SOX regimen showed comparable efficacy and safety to the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen. As the SOX regimen is easier for patients, SOX may be a reasonable substitute for FOLFOX in hepatocellular carcinoma.</p></sec><sec><title>Trial registration</title><p id="Par5">Clinicaltrials.gov <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01429961">NCT01429961</ext-link>. Registered 7 September 2011.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatocellular carcinoma</kwd><kwd>Chemotherapy</kwd><kwd>Phase II</kwd><kwd>Oxaliplatin</kwd><kwd>S-1</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par24">Liver cancer is the second and sixth most frequent cause of death from cancer in men and women, respectively [<xref ref-type="bibr" rid="CR1">1</xref>]. Overall, 70% to 90% of liver cancers are hepatocellular carcinoma, which has poorer prognosis, as most patients are diagnosed at advanced stages and have underlying hepatic dysfunction [<xref ref-type="bibr" rid="CR2">2</xref>]. Sorafenib, a multi-tyrosine kinase inhibitor, has shown efficacy in advanced hepatocellular carcinoma and is the only molecular targeted agent approved for hepatocellular carcinoma based on two phase III trials [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par25">Hepatocellular carcinoma is highly refractory to conventional systemic chemotherapy [<xref ref-type="bibr" rid="CR5">5</xref>]. Although doxorubicin is a palliative treatment in hepatocellular carcinoma, no studies have found strong evidence for the survival benefit of doxorubicin. However, in a phase III clinical trial performed in Asia (EACH trial) which compared the efficacy of FOLFOX (5-fluorouracil (5-FU), leucovorin, and oxaliplatin) and doxorubicin, FOLFOX showed prolonged progression free survival (PFS, 2.93&#160;months vs. 1.77&#160;months) and overall survival (OS, 6.40&#160;months vs. 4.97&#160;months) compared to doxorubicin [<xref ref-type="bibr" rid="CR6">6</xref>]. In a study performed in a Western population, gemcitabine combined with oxaliplatin showed efficacy (median PFS and OS of 4.5 and 11.0&#160;months, respectively) in a multicenter retrospective study [<xref ref-type="bibr" rid="CR7">7</xref>]. Although conventional chemotherapy has never been compared directly with sorafenib, these findings show that conventional chemotherapy may be an option for advanced hepatocellular carcinoma patients.</p><p id="Par26">S-1 is an oral fluoropyrimidine agent, consisting of tegafur (a pro-drug of 5-FU), gimeracil, and oteracil. Gimeracil and oteracil decrease 5-FU anti-metabolite degradation and achieve higher concentrations of 5-FU in the plasma and tumor tissues. Recently, 5-FU has been substituted by oral fluoropyrimidines, such as capecitabine or S-1, to treat many cancers based on phase III study results showing comparable efficacy and better safety profiles with oral fluoropyrimidines [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Therefore, we performed a phase II study to evaluate the efficacy and safety of S-1 and oxaliplatin (SOX) in patients with advanced hepatocellular carcinoma.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and participants</title><p id="Par27">This study was a multicenter, open-label, single-arm, phase 2 trial that evaluated the efficacy of SOX in advanced hepatocellular carcinoma. Patients with hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C that was either refractory or not amenable to locoregional therapy were eligible for the present study. Hepatocellular carcinoma was diagnosed based on 2005 AASLD practice guidelines [<xref ref-type="bibr" rid="CR13">13</xref>]. Either histopathological findings from tumor tissue or non-histological diagnosis based on triphasic CT scan and/or gadolinium enhanced MRI was required [<xref ref-type="bibr" rid="CR13">13</xref>]. Without histological confirmation, liver mass&#8201;&#8805;&#8201;2&#160;cm with characteristic vascularization (either on a triphasic CT scan or gadolinium-enhanced MRI) or AFP&#8201;&#8805;&#8201;200&#160;&#956;g/L was required. In patients with a 1 to 2&#160;cm liver mass, characteristic vascularization on both a triphasic CT scan and gadolinium-enhanced MRI were required with concomitant liver cirrhosis. At least one measurable extrahepatic lesion based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 was required. Other main inclusion criteria were an age of over 18&#160;years; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2; Child-Pugh class A; adequate bone marrow, hepatic, and renal function [absolute neutrophil count (ANC)&#8201;&#8805;&#8201;1500/&#956;L; platelet count &#8805;100,000/&#956;L, total bilirubin &#8804;2 X upper limit of normal (ULN); serum transaminases &#8804;2.5 X ULN; alkaline phosphatase &#8804;2.5 X ULN; serum creatinine &#8804;1.5 X ULN]. Patients with serum transaminases and alkaline phosphatase &#8804;5 X ULN could be included if they had a normal total bilirubin level. Patients were excluded if they had either previous systemic chemotherapy (except prior sorafenib) or history of another malignancy within the last 5&#160;years.</p><p id="Par28">The study protocol was reviewed and approved by the institutional review board of Seoul National University Hospital, Seoul, Korea [H-1010-054-336]. This study was conducted in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects and the Guidelines for Good Clinical Practice (ClinicalTrial.gov Identifier: NCT01429961). Written informed consent was obtained from each patient before enrollment.</p></sec><sec id="Sec4"><title>Treatment and dose modification</title><p id="Par29">S-1 was administered orally at a dose of 40&#160;mg/m<sup>2</sup> twice daily for 14&#160;days (80&#160;mg/m<sup>2</sup>/day), followed by a 7-day rest period. Oxaliplatin was given as a 120&#8211;minute infusion on day 1 of each cycle at a dose of 130&#160;mg/m<sup>2</sup>. Dose reduction of S-1 (30&#160;mg/m<sup>2</sup> twice daily, which is 60&#160;mg/m<sup>2</sup>/day) and Oxaliplatin (100&#160;mg/m<sup>2</sup>) was allowed per the discretion of the treating physician, as most patients with HCC have compensated liver cirrhosis despite a Child-Pugh class A score. Treatment was repeated every 3&#160;weeks until disease progression, unacceptable toxicity, or withdrawal of patient consent. Drug administration was delayed until an ANC of &#8805;1500/&#956;L and platelet counts of &#8805;100,000/&#956;L, and recovery from non-hematological toxicity to baseline or less than or equal to grade 1. S-1 was reduced to a dose of 30&#160;mg/m<sup>2</sup> twice daily (60&#160;mg/m<sup>2</sup>/day) and oxaliplatin was reduced to a dose of 100&#160;mg/m<sup>2</sup> on all subsequent cycles for febrile neutropenia, grade 4 neutropenia, grade 3/4 thrombocytopenia, or greater than or equal to grade 3 non-hematological toxic effects.</p></sec><sec id="Sec5"><title>Assessment</title><p id="Par30">Baseline assessments included medical history, physical examination, electrocardiography, chest X-rays, abdominal and pelvic CT scans (gadolinium enhanced MRI when necessary), complete blood counts, serum electrolytes and chemistry, and urine analysis. Tumor response was assessed using RECIST criteria 1.1, with contrast-enhanced triphasic CT scans at baseline and every two cycles (6&#160;weeks). Toxicity was evaluated at each cycle per the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par31">The primary end point of this study was time to progression (TTP), which was defined as the time from study enrollment to tumor progression. Deaths without progressive disease were censored in the TTP analysis. Secondary end points were OS, PFS, response rate, and toxicity. OS was calculated from the date of study enrollment to the date of death. PFS was defined as the interval between the date of study enrollment and first date of documented progressive disease or the date of death from any cause. Tumor response was assessed using RECIST criteria 1.1. TTP, PFS, and OS were estimated using the Kaplan-Meier method and comparisons were made using log-rank tests. Statistical analysis was performed using SPSS software for Windows, version 18.0 (SPSS, Chicago, IL, USA).</p><p id="Par32">We hypothesized an increased TTP from 2.8&#160;months to 4.0&#160;months in the SOX group. With an alpha of 0.10 and a power of 80%, 34 patients were required for this study. Considering a 10% loss to follow-up rate, the target enrollment was 38 patients.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient characteristics</title><p id="Par33">Between May 27, 2011, and August 28, 2014, 36 patients were enrolled. All patients included in our cohort met the diagnostic criteria for both 2005 and 2010 AASLD guidelines [<xref ref-type="bibr" rid="CR14">14</xref>]. Baseline characteristics of the patients are summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The median patient age was 58&#160;years (range, 21&#8211;74), and 33 patients (91.7%) were male. All patients had at least 1 extrahepatic measurable lesion and good ECOG PS. Per the inclusion criteria, all patients were classified as Child-Pugh class A and had adequate hepatic function. On the baseline CT/MRI, 94.4% (34/36) showed liver cirrhosis. Of the 36 patients, 31 patients were treated with prior sorafenib or locoregional therapy (TACE, PEIT, or RFA). One patient did not receive either prior sorafenib or locoregional therapy.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table-wrap-foot><p>Abbreviations: <italic>ECOG</italic>, Eastern Cooperative Oncology Group, <italic>PS</italic> performance status</p><p><sup>a</sup>includes transcatheter arterial chemoembolization (TACE), percutaneous ethanol injection therapy (PEIT), and radiofrequency ablation (RFA)</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Efficacy</title><p id="Par34">Response evaluation was available for all 36 patients. One patient achieved a complete response (CR, 2.8%), 4 had a partial response (PR, 11.1%), 13 had stable disease (SD, 36.1%), and 18 had progressive disease (PD, 50.0%). The overall response rate (ORR) was 13.9% and the disease control rate (DCR) was 50.0%.</p><p id="Par35">With a median follow-up of 10.9&#160;months, 35 progression events and 34 deaths occurred. PFS and TTP were the same in our cohort as no patients died without progression. The median TTP and PFS were 3.0&#160;months (95% confidence interval (CI), 0.7&#8211;5.3) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), and the median OS was 10.3&#160;months (95% CI, 6.4&#8211;14.3) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The trial did not meet its primary end point of a 4-month TTP. Bone metastasis was associated with poorer survival (hazard ratio (HR) for TTP 2.31, 95% CI 1.02&#8211;5.21, <italic>p</italic>&#8201;=&#8201;0.045) (HR for OS 2.36, 95% CI 1.05&#8211;5.30, <italic>p</italic>&#8201;=&#8201;0.037) (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Gender, age, PS, AFP level, PIVKA level, prior sorafenib treatment, prior locoregional therapy, and lung or liver metastasis were unassociated with TTP and OS. In patients treated with prior sorafenib (31/36, 86.6%), median TTP and OS were 3.0 (95% CI, 1.2&#8211;4.8) months and 9.5 (95% CI, 5.4&#8211;13.7) months, respectively.<fig id="Fig1"><label>Fig. 1</label><caption><p>Kaplan&#8211;Meier survival curve for time to progression</p></caption><graphic xlink:href="12885_2018_4039_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan&#8211;Meier survival curve for overall survival</p></caption><graphic xlink:href="12885_2018_4039_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Kaplan&#8211;Meier curves of TTP and OS according to the presence of bone metastasis. Abbreviations: TTP, time to progression; OS, overall survival</p></caption><graphic xlink:href="12885_2018_4039_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec10"><title>Toxicity</title><p id="Par36">Patients received a total of 199 treatment cycles, with a median of 3&#160;cycles (range, 1&#8211;27) per patient. Study treatments were discontinued in 2 patients (5.5%) because of severe adverse events, including spontaneous bacterial peritonitis and hepatocellular carcinoma rupture. Nine patients (25.0%) started chemotherapy at a reduced dose and 27 (75.0%) started chemotherapy at the regular dose. Of the 27 patients who started chemotherapy at the regular dose, 11 (40.7%) had their dose reduced during the chemotherapy cycle due to toxicity. This includes four cases of grade 3 thrombocytopenia, three cases of grade 3 diarrhea, one case of grade 3 neutropenia, one case of grade 3 sensory neuropathy, one case of grade 2 gastrointestinal bleeding, and one case of septic shock due to pneumonia. All 11 patients recovered from the adverse event and received subsequent chemotherapy at a reduced dose. No treatment-related death or grade 4 toxicity occurred during the study. Detailed toxic events per patient are shown in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. The most common adverse event of any grade was sensory neuropathy (52.8%), followed by thrombocytopenia (41.7%), diarrhea (38.9%), nausea (36.1%), anorexia (33.3%), and neutropenia (30.1%). The most common grade 3 toxicities were neutropenia (13.9%), thrombocytopenia (13.9%), and diarrhea (8.3%).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Toxicity profile</p></caption><table-wrap-foot><p>Abbreviations: <italic>AST</italic> Aspartate aminotransferase, <italic>ALT</italic> Alanine aminotransferase, <italic>N/A</italic> not assessed</p><p><sup>a</sup>Toxicities with Grade 2 or more were counted for these items</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par37">The results of our phase 2 study show that the SOX regimen may be an option for managing patients with advanced hepatocellular carcinoma. The median TTP/PFS was 3.0&#160;months (95% CI, 0.7&#8211;5.3), median OS was 10.3&#160;months (95% CI, 6.4&#8211;14.3), ORR was 13.9%, and DCR was 50.0%. Although the study did not meet its primary end point (TTP of 4.0&#160;months), SOX showed comparable efficacy with FOLFOX in the EACH trial (PFS: 2.93&#160;months, OS: 6.40&#160;months, ORR: 8.15%, DCR: 52.17%) [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par38">In this study, no grade 4 toxicity resulted from the SOX regimen. Most adverse events were grade 1/2 and common grade 3 toxicities were neutropenia and thrombocytopenia. However, most patients with grade 3 toxicity were easily managed and tolerated after a dose reduction. Although 2 patients stopped chemotherapy due to severe adverse events, these events (spontaneous bacterial peritonitis and hepatocellular carcinoma rupture) were not directly associated with chemotherapy toxicity. Although we cannot directly compare our results to the EACH trial, the SOX regimen showed a better safety profile than the FOLFOX regimen [<xref ref-type="bibr" rid="CR6">6</xref>]. Fifty-five percent of patients treated with FOLFOX had an adverse event over grade 3, and 6% died from the severe adverse event. In addition, 23% of patients discontinued FOLFOX chemotherapy due to adverse events.</p><p id="Par39">Sorafenib is the current standard of care in managing advanced hepatocellular carcinoma. Several studies have investigated the efficacy of novel molecular-targeted agents (sunitinib, everolimus, brivanib, linifanib, and ramucirumab) in first-line or second-line settings [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR20">20</xref>]. However, all studies were negative except for regorafenib which showed efficacy in sorafenib-resistant hepatocellular carcinoma [<xref ref-type="bibr" rid="CR21">21</xref>]. Currently, few options exist to manage patients with advanced hepatocellular carcinoma. In addition, sorafenib efficacy is modest in Asian patients compared to Western patients [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Although FOLFOX has not been compared directly with sorafenib, previous results support FOLFOX as a reasonable option for managing advanced hepatocellular carcinoma. In this study we evaluated the efficacy of SOX in advanced hepatocellular carcinoma. S-1 is an oral fluoropyrimidine which can substitute 5-FU in many cancers. Our results show that SOX is comparable to FOLFOX and may be an alternative to FOLFOX. Moreover, TTP and OS were unaffected by whether the patients received prior sorafenib or locoregional therapy. In a single center retrospective study, the SOX regimen showed efficacy comparable to that of sorafenib in advanced hepatocellular carcinoma [<xref ref-type="bibr" rid="CR22">22</xref>]. Thus, the SOX regimen may be an effective option in pre-treated or treatment-na&#239;ve advanced hepatocellular carcinoma patients.</p><p id="Par40">In this study, bone metastasis was associated with poorer survival in patients treated with the SOX regimen. As this study was a single-arm study, we cannot determine whether this poorer survival was due to its innate aggressive biology of the metastasis or its resistance to chemotherapy. Although bone is a frequent extrahepatic metastatic site, its prognostic role is unknown [<xref ref-type="bibr" rid="CR23">23</xref>]. Evidence shows that hepatocellular carcinoma patients with bone metastasis may derive survival benefit from locoregional and/or systemic chemotherapy compared to the best supportive care (OS, 9.7 vs. 2.9&#160;months, log-rank test <italic>p</italic>&#8201;=&#8201;0.081) [<xref ref-type="bibr" rid="CR24">24</xref>]. Prognostic and predictive roles of bone metastasis in patients with hepatocellular carcinoma should be assessed in larger studies.</p></sec><sec id="Sec12"><title>Conclusion</title><p id="Par41">This phase II study indicates that combination therapy with S-1 and oxaliplatin may be effective in patients with advanced hepatocellular carcinoma. Toxicity was moderate, but manageable. Patients with bone metastasis showed poorer survival following SOX treatment. As the SOX regimen shows comparable efficacy with FOLFOX and is easier for patients, SOX may be a reasonable substitute for FOLFOX in patients with advanced hepatocellular carcinoma.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>5-FU</term><def><p id="Par6">5-fluorouracil</p></def></def-item><def-item><term>ANC</term><def><p id="Par7">Absolute neutrophil count</p></def></def-item><def-item><term>CI</term><def><p id="Par8">Confidence interval</p></def></def-item><def-item><term>CR</term><def><p id="Par9">Complete response</p></def></def-item><def-item><term>DCR</term><def><p id="Par10">Disease control rate</p></def></def-item><def-item><term>ECOG PS</term><def><p id="Par11">Eastern Cooperative Oncology Group performance status</p></def></def-item><def-item><term>FOLFOX</term><def><p id="Par12">5-fluorouracil, leucovorin, and oxaliplatin</p></def></def-item><def-item><term>HR</term><def><p id="Par13">Hazard ratio</p></def></def-item><def-item><term>ORR</term><def><p id="Par14">Overall response rate</p></def></def-item><def-item><term>OS</term><def><p id="Par15">Overall survival</p></def></def-item><def-item><term>PD</term><def><p id="Par16">Progressive disease</p></def></def-item><def-item><term>PFS</term><def><p id="Par17">Progression free survival</p></def></def-item><def-item><term>PR</term><def><p id="Par18">Partial response</p></def></def-item><def-item><term>RECIST</term><def><p id="Par19">Response Evaluation Criteria in Solid Tumors</p></def></def-item><def-item><term>SD</term><def><p id="Par20">Stable disease</p></def></def-item><def-item><term>SOX</term><def><p id="Par21">S-1 and oxaliplatin</p></def></def-item><def-item><term>TTP</term><def><p id="Par22">Time to progression</p></def></def-item><def-item><term>ULN</term><def><p id="Par23">Upper limit of normal</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We would like to thank all study participants and medical assistants from cooperating hospitals</p><sec id="FPar1"><title>Funding</title><p id="Par42">There was no funding for the present study.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par43">Any request for data and materials should be made in writing to the corresponding author, and these will be considered.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#8217; contributions</title><p>KHL, DWL, and TYK were involved in study concept and design. KHL, HJK, TYK, JSK, SWH, DYO, JHK, SAI, and TYK involved in data acquisition. Analysis and interpretation of data was done by DWL and KHL. Manuscript writing was made by DWL, KHL, and TYK. Manuscript review and final approval was done by DWL, KHL, HJK, TYK, JSK, SWH, DYO, JHK, SAI, and TYK. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par44">The study protocol was reviewed and approved by the institutional review board of Seoul National University Hospital, Seoul, Korea [H-1010-054-336]. This study was carried out in accordance with the recommendations of the Declaration of Helsinki for biomedical research involving human subjects and the Guidelines for Good Clinical Practice (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrial.gov">ClinicalTrial.gov</ext-link> Identifier: NCT01429961). Written informed consent was obtained from each patient before enrollment.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par45">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par46">The authors declare that they have no competing interest.</p></sec><sec id="FPar6"><title>Publisher&#8217;s Note</title><p id="Par47">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics, 2012</article-title><source>CA Cancer J Clin</source><year>2015</year><volume>65</volume><fpage>87</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/caac.21262</pub-id><?supplied-pmid 25651787?><pub-id pub-id-type="pmid">25651787</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>MB</given-names></name><name><surname>Jaffe</surname><given-names>D</given-names></name><name><surname>Choti</surname><given-names>MM</given-names></name><name><surname>Belghiti</surname><given-names>J</given-names></name><name><surname>Curley</surname><given-names>S</given-names></name><name><surname>Fong</surname><given-names>Y</given-names></name><name><surname>Gores</surname><given-names>G</given-names></name><name><surname>Kerlan</surname><given-names>R</given-names></name><name><surname>Merle</surname><given-names>P</given-names></name><name><surname>O'Neil</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute clinical trials planning meeting</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>3994</fpage><lpage>4005</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.28.7805</pub-id><?supplied-pmid 20679622?><pub-id pub-id-type="pmid">20679622</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Ricci</surname><given-names>S</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Hilgard</surname><given-names>P</given-names></name><name><surname>Gane</surname><given-names>E</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>de Oliveira</surname><given-names>AC</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Forner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0708857</pub-id><?supplied-pmid 18650514?><pub-id pub-id-type="pmid">18650514</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Tsao</surname><given-names>CJ</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Oncol.</source><year>2009</year><volume>10</volume><fpage>25</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(08)70285-7</pub-id><?supplied-pmid 19095497?><pub-id pub-id-type="pmid">19095497</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AX</given-names></name></person-group><article-title>Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><fpage>790</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.11-7-790</pub-id><?supplied-pmid 16880238?><pub-id pub-id-type="pmid">16880238</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>T-S</given-names></name><name><surname>Bhudhisawasdi</surname><given-names>V</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Randomized, multicenter, open-label study of Oxaliplatin plus fluorouracil/Leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced Hepatocellular carcinoma from Asia</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3501</fpage><lpage>3508</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.44.5643</pub-id><?supplied-pmid 23980077?><pub-id pub-id-type="pmid">23980077</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaanan</surname><given-names>A</given-names></name><name><surname>Williet</surname><given-names>N</given-names></name><name><surname>Hebbar</surname><given-names>M</given-names></name><name><surname>Dabakuyo</surname><given-names>TS</given-names></name><name><surname>Fartoux</surname><given-names>L</given-names></name><name><surname>Mansourbakht</surname><given-names>T</given-names></name><name><surname>Dubreuil</surname><given-names>O</given-names></name><name><surname>Rosmorduc</surname><given-names>O</given-names></name><name><surname>Cattan</surname><given-names>S</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><etal/></person-group><article-title>Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study</article-title><source>J Hepatol</source><year>2013</year><volume>58</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.09.006</pub-id><?supplied-pmid 22989572?><pub-id pub-id-type="pmid">22989572</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Starling</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Coxon</surname><given-names>F</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Daniel</surname><given-names>F</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa073149</pub-id><?supplied-pmid 18172173?><pub-id pub-id-type="pmid">18172173</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ajani</surname><given-names>JA</given-names></name><name><surname>Rodriguez</surname><given-names>W</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Moiseyenko</surname><given-names>V</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Gorbunova</surname><given-names>V</given-names></name><name><surname>Vynnychenko</surname><given-names>I</given-names></name><name><surname>Garin</surname><given-names>A</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Falcon</surname><given-names>S</given-names></name></person-group><article-title>Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><fpage>1547</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.4706</pub-id><?supplied-pmid 20159816?><pub-id pub-id-type="pmid">20159816</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Diaz-Rubio</surname><given-names>E</given-names></name><name><surname>Scheithauer</surname><given-names>W</given-names></name><name><surname>Figer</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Koski</surname><given-names>S</given-names></name><name><surname>Lichinitser</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>TS</given-names></name><name><surname>Rivera</surname><given-names>F</given-names></name><etal/></person-group><article-title>Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>2006</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9898</pub-id><?supplied-pmid 18421053?><pub-id pub-id-type="pmid">18421053</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porschen</surname><given-names>R</given-names></name><name><surname>Arkenau</surname><given-names>HT</given-names></name><name><surname>Kubicka</surname><given-names>S</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><name><surname>Seufferlein</surname><given-names>T</given-names></name><name><surname>Freier</surname><given-names>W</given-names></name><name><surname>Kretzschmar</surname><given-names>A</given-names></name><name><surname>Graeven</surname><given-names>U</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Hinke</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO colorectal study group</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4217</fpage><lpage>4223</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.09.2684</pub-id><?supplied-pmid 17548840?><pub-id pub-id-type="pmid">17548840</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muro</surname><given-names>K</given-names></name><name><surname>Boku</surname><given-names>N</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Tsuji</surname><given-names>A</given-names></name><name><surname>Sameshima</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Denda</surname><given-names>T</given-names></name><name><surname>Ina</surname><given-names>K</given-names></name><name><surname>Nishina</surname><given-names>T</given-names></name><etal/></person-group><article-title>Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)</article-title><source>Lancet Oncol.</source><year>2010</year><volume>11</volume><fpage>853</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(10)70181-9</pub-id><?supplied-pmid 20708966?><pub-id pub-id-type="pmid">20708966</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>Practice guidelines committee AAftSoLD: management of hepatocellular carcinoma</article-title><source>Hepatology</source><year>2005</year><volume>42</volume><fpage>1208</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1002/hep.20933</pub-id><?supplied-pmid 16250051?><pub-id pub-id-type="pmid">16250051</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>M</given-names></name></person-group><article-title>American Association for the Study of liver D: management of hepatocellular carcinoma: an update</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>1020</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1002/hep.24199</pub-id><?supplied-pmid 21374666?><pub-id pub-id-type="pmid">21374666</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cainap</surname><given-names>C</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>WT</given-names></name><name><surname>Chung</surname><given-names>IJ</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Chen</surname><given-names>PJ</given-names></name><name><surname>Toh</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><fpage>172</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.54.3298</pub-id><?supplied-pmid 25488963?><pub-id pub-id-type="pmid">25488963</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Lin</surname><given-names>DY</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Poggi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>4067</fpage><lpage>4075</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.45.8372</pub-id><?supplied-pmid 24081937?><pub-id pub-id-type="pmid">24081937</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Philip</surname><given-names>PA</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Hu</surname><given-names>TH</given-names></name><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3517</fpage><lpage>3524</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.48.4410</pub-id><?supplied-pmid 23980084?><pub-id pub-id-type="pmid">23980084</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Decaens</surname><given-names>T</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Boucher</surname><given-names>E</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Assenat</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><etal/></person-group><article-title>Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><fpage>3509</fpage><lpage>3516</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.47.3009</pub-id><?supplied-pmid 23980090?><pub-id pub-id-type="pmid">23980090</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Assenat</surname><given-names>E</given-names></name><name><surname>Cattan</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>Vogel</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial</article-title><source>JAMA</source><year>2014</year><volume>312</volume><fpage>57</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.7189</pub-id><?supplied-pmid 25058218?><pub-id pub-id-type="pmid">25058218</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Park</surname><given-names>JO</given-names></name><name><surname>Ryoo</surname><given-names>BY</given-names></name><name><surname>Yen</surname><given-names>CJ</given-names></name><name><surname>Poon</surname><given-names>R</given-names></name><name><surname>Pastorelli</surname><given-names>D</given-names></name><name><surname>Blanc</surname><given-names>JF</given-names></name><name><surname>Chung</surname><given-names>HC</given-names></name><name><surname>Baron</surname><given-names>AD</given-names></name><name><surname>Pfiffer</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial</article-title><source>Lancet Oncol</source><year>2015</year><volume>16</volume><fpage>859</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00050-9</pub-id><?supplied-pmid 26095784?><pub-id pub-id-type="pmid">26095784</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Merle</surname><given-names>P</given-names></name><name><surname>Granito</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>Y-H</given-names></name><name><surname>Bodoky</surname><given-names>G</given-names></name><name><surname>Yokosuka</surname><given-names>O</given-names></name><name><surname>Rosmorduc</surname><given-names>O</given-names></name><name><surname>Breder</surname><given-names>V</given-names></name><name><surname>Gerolami</surname><given-names>R</given-names></name><name><surname>Masi</surname><given-names>G</given-names></name><etal/></person-group><article-title>LBA-03Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial</article-title><source>Ann Oncol</source><year>2016</year><volume>27</volume><fpage>ii140</fpage><lpage>ii141</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdw237.03</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Liao</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma</article-title><source>Pharmazie</source><year>2014</year><volume>69</volume><fpage>759</fpage><lpage>763</lpage><?supplied-pmid 25985566?><pub-id pub-id-type="pmid">25985566</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natsuizaka</surname><given-names>M</given-names></name><name><surname>Omura</surname><given-names>T</given-names></name><name><surname>Akaike</surname><given-names>T</given-names></name><name><surname>Kuwata</surname><given-names>Y</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Karino</surname><given-names>Y</given-names></name><name><surname>Toyota</surname><given-names>J</given-names></name><name><surname>Suga</surname><given-names>T</given-names></name><name><surname>Asaka</surname><given-names>M</given-names></name></person-group><article-title>Clinical features of hepatocellular carcinoma with extrahepatic metastases</article-title><source>J Gastroenterol Hepatol</source><year>2005</year><volume>20</volume><fpage>1781</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2005.03919.x</pub-id><?supplied-pmid 16246200?><pub-id pub-id-type="pmid">16246200</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SU</given-names></name><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><name><surname>Nah</surname><given-names>HJ</given-names></name><name><surname>Chon</surname><given-names>CY</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name></person-group><article-title>Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors</article-title><source>J Cancer Res Clin Oncol</source><year>2008</year><volume>134</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1007/s00432-008-0410-6</pub-id><?supplied-pmid 18483745?><pub-id pub-id-type="pmid">18483745</pub-id></element-citation></ref></ref-list></back></article>